key: cord-0426638-wg8wd81m
authors: Sindhi, R.; Ashokkumar, C.; Singh, V.; Spishock, B.; Saunders, M.; Mabasa, A.; Sindhi, E.; Sethi, P.; Reddy, A.; Subramaniam, S.; Nibhanupudy, B.
title: Cellular and Antibody Immunity after COVID-19 Vaccination at >4-Month Follow Up in Immunocompetent and Immunocompromised Subjects
date: 2021-10-11
journal: nan
DOI: 10.1101/2021.10.07.21257459
sha: 6da386220b82b7f0bc4af1025cd355ae3acda018
doc_id: 426638
cord_uid: wg8wd81m

We evaluated post-vaccination immunity after COVID-19 vaccination with serial changes in cellular and antibody responses to the spike protein S, its S2 component which is conserved between SARS-CoV-2 and human coronaviruses, and the S1 component, which is specific to SARS-CoV-2 and also contains its receptor binding domain (RBD). In 21 healthy immunocompetent subjects all of whom demonstrated circulating IgG antibodies 4 months after mRNA1273 or BNT162b vaccination, a) the strength of S-IgG was stable while RBD-IgG declined, b) S2-reactive B-cell frequencies increased progressively (p=0.002) c) S1-reactive CD8+T-cells and CD19+B-cells were undetectable after a transient increase, and d) monocytic and polymorphonuclear myeloid-derived suppressor cells (M-MDSC, PMN-MDSC) increased after the first vaccine dose. Compared with 4-month measurements from immunocompetent subjects, single samples from 20 vaccinated immunocompromised (IC) subjects revealed a) circulating S-IgG and RBD-IgG in 13 (65%) and 9 (45%) subjects, respectively, b) no differences in S2-reactive T- and B-cells, c) undetectable S1-reactive T- and B-cells, and d) fewer S-reactive CD8+T-cells and CD19+B-cells (p<0.05). Among 11 IC recipients who failed to make RBD-IgG, frequencies of PMN-MDSC were significantly higher (p<0.0004) compared with IC or immunocompetent subjects with RBD-IgG. COVID-19 vaccination induces stable antibodies to the spike protein and expands circulating B-cells reactive to the conserved spike protein sequence in immunocompetent subjects. MDSC which are known to suppress T- and B-cells, and which increase after vaccination, may limit post-vaccination responses especially among immunocompromised subjects. Antibody and cellular responses to SARS-CoV-2-specific spike antigenic sequences appear to be less durable.

Cellular immunity to the COVID-19 coronavirus is of great interest because of concerns about 39 vaccine efficacy against emerging SARS-CoV-2 variants and the lower seroconversion rates after 40 vaccination in older and immunosuppressed subjects (1-3). Following 41 antibodies only develop in a half of transplant recipients, inflammatory bowel disease patients 42 receiving anti-tumor necrosis factor antibodies, and those with hematologic malignancies (3-5). The 43

seroconversion rate is only 23% in those with B-cell malignancies (5). 44

The post-vaccination immune response likely recapitulates the discordant kinetics of T-cell 45 responsiveness and SARS-CoV-2 antibodies observed by us early after moderate to severe COVID-46 19 infection (6). Although anti-spike IgG antibodies appeared within two weeks after infection in immunocompetent subjects, T-cells from severely ill COVID-19 patients displayed 48 impaired in vitro reactivity to the spike antigen, while circulating myeloid derived suppressor cells 49

(MDSC) increased significantly. MDSC arise during acute viral infections and suppress T-cells (7-9). 50

In immunosuppressed transplant recipients, we observed a lower incidence of antibody to the SARS-51

CoV-2-specific receptor binding domain (RBD) of the spike protein, significantly impaired T-cell 52 responses to stimulation with conserved spike antigen, and a 34% incidence of CMV co-infection 53 early after COVID-19 infection. The S antigenic sequence consists of the less conserved N-terminal 54 S1 component, which contains the receptor binding domain (RBD), and the C-terminal S2 sequence 55 which is relatively conserved between human coronaviruses and SARS-CoV-2 (10). 56

To better understand the post-vaccination response, we now characterize T-cell, B-cell and IgG 57 responses to S antigenic sequences before and after each dose of mRNA1273 and BNT162b2 58 vaccines before and over the course of 4 months after starting vaccination in 21 healthy 59 immunocompetent subjects. Single samples from 20 immunocompromised (IC) subjects vaccinated 60 with the mRNA vaccines and Ad26.COV2.S are also evaluated with the same assays. 61 

IgG in healthy immunocompetent subjects: The incidence of RBD-IgG and spike-IgG increased from 85 17/21 and 19/21 two weeks after the first dose, to all 21 subjects being positive for either antibody 86 two weeks after the second dose. By month 4, 1/21 subjects had turned negative for RBD-IgG. This 87 subject has since received a booster. All those with spike-IgG remained positive. 88 RBD-IgG strength inferred from the mean ± SEM OD 490 increased significantly from pre-dose to the 89 first (p=2.8E-05) and from the first to the second doses (p=1E-04). This strength decreased 90 significantly between the second dose and month 4 after vaccination, from OD 490 of 2.87 +/-0.013 to 91 2.15 +/-0.2, p=0.005. The OD 490 for anti-S IgG also increased significantly after each dose but was 92 unchanged after the second dose to month 4 (p=0.573, NS). These OD 490 values were also 93 noteworthy for the larger interindividual variation after the first vaccine dose, and smaller variation 94 after the second dose ( Figure 1 ). 95

To evaluate whether the long-term antibody response depended on early antibody kinetics, subjects 96

were arbitrarily divided into those with median OD 490 less than and greater than the median of 1.2 97 after the first dose. Four months after vaccination, antibody strength for RBD-IgG (p=0.008) and 98

Spike-IgG (p=0.1, NS) was lower in those subjects with lower median OD 490 after the first dose, 99 compared with those with higher OD 490 after the first dose. 100

As reported in a companion study, we first 101 established an assay to examine post-infectious immunity with S-antigen specific T-cells. We 102 established that CD154 is co-expressed with IFNγ, a marker of cytotoxic T-cells, in PBL from 5 103 healthy human subjects, stimulated overnight with the S peptide mixture (Supplementary Figure 1) . 104

Median (range) frequencies of S-reactive T-cells that co-expressed both markers were 3.1% (1.1-105 10.3), and greatly exceeded S-reactive T-cells that expressed either CD154, 0.2% (0.1-0.2) or IFNγ 106 0% (0-0.1), respectively. Because nearly all S-reactive IFNγ+T-cells co-express CD154, using the 107 single marker CD154 would overestimate S-reactive IFNγ+T-cells by 0.2% divided by the sum of 108 0.2% and 3.1% times 100, or 6%. Similarly, in four patients with COVID-19 infection, S-reactive 109 CD154+ IFNγ+T-cells were 0.74% (0.48-0.93), and greatly exceeded CD154+T-cells, 0.03% (0-110 0.08) or IFNγ+T-cells 0% (0-0) respectively. Because all S-reactive IFNγ+T-cells co-express CD154, 111

using the single marker CD154 in patients with COVID-19 would overestimate S-reactive IFNγ+T-112 cells by 3.9%. In three healthy human subjects, median (range) frequencies of S-reactive B-cells that 113 co-expressed IL-6 and CD154 were 4.9% (4.7-13.1) and greatly exceeded B-cells that expressed 114 either CD154, 0.4% (0.3-0.4) or IL-6, 0% (0-0), respectively. Because all S-reactive IL-6+B-cells co-115 express CD154, using the single marker CD154 would overestimate S-antigen reactive IL-6+B-cells 116 by 7.54%. Thus, S-reactive T-and B-cells capture all S-antigen reactive IFNγ+T-cells, and IL-6+B-117 cells, respectively, and overestimate these cell types by only 3.9-7.5%. In subsequent assays, CD154 118 was used in lieu of the markers IFNγ an IL-6 in T-and B-cells, respectively. 119 B-cells responsive to the conserved S2 increase progressively, while those to SARS-CoV-2 specific S1 120 spike antigenic sequence increase transiently after vaccination: S2 reactive T-and B-cells are present 121 in many healthy individuals who have not been exposed to SARS-CoV-2 because the S2 component 122 of the spike antigen shares sequence similarities with the human coronaviruses which have caused 123 seasonal flu-like illnesses since the 1960s (10, 11). S2-reactive B-cells decreased after the first 124 This is a provisional file, not the final typeset article vaccine dose compared with pre-vaccination levels but increased progressively at subsequent time 125 points to significantly higher levels (p=0.002, K-W rank sum test) ( Figure 2 ). We have previously 126 categorized the population distribution of S2 reactive B-cell frequencies measured in a sample of 47 127 independent healthy human subjects who had not been exposed to SARS-CoV-2, into four quartiles, 128 Q1-Q4. Of 21 subjects in the current study, pre-vaccination S2-reactive B-cell frequencies placed 9 129 subjects in Q1, one subject in Q2, 7 in Q3 and 4 in Q4 (Figure 3 ). By 4 months after vaccination, S2-130 reactive B-cell frequencies were in Q3 (n=9) or Q4 (n=11) in 20 of 21 subjects. In the remaining 131 subject, S2-reactive B-cell frequencies were in Q2. None of the 21 vaccinated subjects showed 132 frequencies in the first quartile. S-reactive B-cells also increased steadily from after the first vaccine 133 dose to month 4 (p=0.015). S1-reactive B-cells increased significantly after the second vaccine dose 134 compared with pre-vaccination levels but were undetectable 4 months after vaccination (p=0.019). 135

T-cell responsiveness to the SARS-CoV-2-specific S1 sequence but not the conserved S2 sequence 136

increases transiently. CD8 T-cells that were reactive to the SARS-CoV-2-specific spike antigenic 137 sequence S1 were absent before vaccination and increased transiently to levels higher than pre-138 vaccination levels after the second vaccine dose (Figure 2 ). S1-reactive cells were not detectable 4 139 months after vaccination. Differences between observations at all four time points were significant 140 (p=0.002, K-W rank sum test). S2-and S-reactive CD4 and CD8 cells decreased after the first 141 vaccine dose and approached but did not exceed pre-vaccination levels at subsequent timepoints 142 during the first four months (Figure 2 ). 143 To identify the origins of between-group differences in cellular immunity, we compared 20 of 21 158 immunocompetent subjects with detectable RBD-IgG with 9 IC subjects, also with detectable RBD-159

IgG and 11 IC subjects without detectable RBD-IgG. S-reactive CD4 and S-reactive B-cell 160 frequencies differed between three groups (p<0.05, Kruskal-Wallis test). In pairwise comparisons, 161 these differences arose from significantly lower frequencies for these two cell types in each IC 162

subgroup, compared with immunocompetent subjects. No such differences were seen between the 163 two IC subgroups. Interestingly, significant differences in PMN-MDSC frequencies between three 164 groups (p=0.002, K-W test) arose from significantly higher PMN-MDSC frequencies in IC patients 165 who failed to make RBD-IgG compared with IC or healthy subjects with RBD-IgG after vaccination 166 (p<0.0004). Differences between three groups in RBD-IgG strength (p=6.9E-06) similarly arose 167 from lower antibody strength in the RBD-IgG negative IC subjects (p<9.3E-07). 168 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. sequence, which is more specific for SARS-CoV-2 (Figures 1 and 2) . In contrast, spike-IgG strength 172 remains stable between the second dose and the fourth month. The most noteworthy change during 173 this time period is a progressive increase in S2 and S-reactive B-cells (Figures 2 and 3) . This change 174

contrasts with a numeric but not statistically significant decrease in S2 and S-reactive CD4 and CD8 175

T-cells after the first vaccine dose and a return to pre-vaccination levels. After the first vaccine dose, 176

M-MDSC and PMN-MDSC increase (Figure 4) . Decreased T-cell responses to the spike protein and 177

increased MDSC frequencies have been observed early after COVID-19 infection (Ashokkumar)(6). 178

Thus, the T-cell response to vaccines recapitulates the effects of COVID-19 infection. 179

These observations lead to several inferences. First, the cellular and antibody response to S1 or its 180 RBD component, which has some sequence-specificity for SARS-CoV-2 is shorter lived compared 181

with Spike-IgG which remains stable until the fourth month. Emerging data at 6 months which will 182 be reported demonstrates stability in the strength of Spike IgG. In this setting, the rationale for early 183 boosters is the declining RBD-IgG response and not the spike-IgG response. Table 1 ), compared with one such recipient in IC with RBD-214 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 11, 2021. ; https://doi.org/10.1101/2021.10.07.21257459 doi: medRxiv preprint This is a provisional file, not the final typeset article IgG. In the RBD-IgG-negative IC group, belatacept which inhibits donor-specific antibody 215 development in transplant recipients and velcade which is used to treat antibody mediated rejection in 216 transplant patients were used in a subject with multiple myeloma and a kidney transplant recipient, 217

respectively. To better understand the post-vaccine antibody response in IC subjects, the role of 218 MDSC and immunosuppressive regimens will need ongoing reassessment. 219

Vaccinated IC subjects also revealed a heterogenous cellular response to the conserved S2 and the 220 complete S antigenic sequences suggesting varying immunogenicity of the spike antigenic sequences 221

( Figure 5 ). The frequencies of S2-reactive CD4, CD8 and CD19 B-cells were not significantly 222 different between immunocompetent subjects and the two IC sub cohorts, one of which failed to 223 make RBD-IgG. This observation is of interest because S2-reactive B-cell frequencies rose 224

progressively until the fourth month after vaccination. Thus, similar ranges of S2-reactive B-cell 225 frequencies in immunocompetent and IC subjects at an average of 132 and 101 days after 226 vaccination, respectively, would imply a post vaccination augmentation in both types of subjects, and 227 also suggest that pre-existing immunity due to previous exposure to human coronaviruses may offer 228 some protection in both types of subjects. Serial observations are needed in IC subjects. In contrast, 229

S-reactive CD4+T-cell and B-cell frequencies were significantly lower in the IC sub cohorts 230 compared with immunocompetent subjects but similar between the two IC sub cohorts, one of which 231 failed to produce RBD-IgG after vaccination. The dynamic range of S-reactive cell frequencies is 232 larger than S2-reactive cells and may better discern differences between groups. Other reasons may 233

include a greater immunogenicity of the S1 and S2 components together, than either component 234 alone. In support of this inference, T-and B-cells responsive to stimulation with the isolated S1 235 antigenic mixture were not detected 4 months after vaccination, suggesting that this component may 236 be less immunogenic by itself. This heterogeneity suggests that T-and B-cells respond variably to the 237 spike antigenic components. Further, cellular and humoral immunity does not go hand in hand in IC 238 subjects. Thus, protective immunity may be an aggregate of many known and unknown responses to 239 vaccination. 240

In conclusion, COVID-19 vaccination induces a transient increase in cellular and antibody responses 241

to the SARS-CoV-2-specific S1 spike antigenic sequence. A sustained antibody response to the 242 complete spike protein that is stable for at least 4 months is accompanied by a progressive increase in 243 B-cells that are responsive to this spike protein, and its component that is conserved between the 244 human coronaviruses and SARS-CoV-2. Although half of the IC subjects in this study failed to 245 seroconvert after vaccination, T-cell and B-cell reactive to the conserved S2 component of the spike 246 protein may provide cellular immunity at levels similar to those seen in IC and immunocompetent 247 subjects who seroconverted after vaccination. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 11, 2021. ; https://doi.org/10.1101/2021.10.07.21257459 doi: medRxiv preprint

305 Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum 306 Samples

308 Delayed Antibody and T-Cell

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ 312 Transplant Recipients

314 Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-315 19 SARS-CoV-2 vaccines in patients with IBD

Suboptimal response to COVID-318 19 mRNA vaccines in hematologic malignancies patients

321 Impaired T-cell and antibody immunity after COVID-19 infection in chronically 322 immunosuppressed transplant recipients

Expansion of 324 myeloid-derived suppressor cells in patients with severe coronavirus disease

327 Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

Phylogenetic 332 Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary 333 Distinct and Proteolytically Sensitive Activation Loop

History and recent advances in coronavirus discovery

339 Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered 340 individuals following mRNA vaccination

SARS-CoV-2-343 reactive T cells in healthy donors and patients with COVID-19

346 Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease 347 and Unexposed Individuals

350 Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Cross-reactive 353 CD4(+) T cells enhance SARS-CoV-2 immune responses upon infection and vaccination

356 Myeloid-derived suppressor cells modulate B-cell responses

Myeloid-359 derived suppressor cells control B cell accumulation in the central nervous system during 360 autoimmunity

Myeloid-derived 362 suppressor cells expand after transplantation and their augmentation increases graft survival

Myeloid-derived 365 suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers

Differential expansion of circulating human MDSC subsets in patients with cancer, 369 infection and inflammation

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

This is a provisional file, not the final typeset article